

Commission Implementing Decision (EU) 2020/1729 of 17 November 2020 on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria and repealing Implementing Decision 2013/652/EU (notified under document C(2020) 7894) (Only the English version is authentic) (Text with EEA relevance)

Article 1	Subject matter and scope
Article 2	Definitions
Article 3	Sampling framework and analysis
Article 4	Annual AMR reporting and assessment
Article 5	Publication of the data
Article 6	Repeal
Article 7	Application
Article 8	Addressees
	Signature

---

ANNEX

PART A

Sampling framework and analysis

1. Origin of bacterial isolates subject to antimicrobial susceptibility testing
2. Sampling frequency
3. Sampling design and sample size
  - 3.1. At slaughterhouse level
    - (a) Sampling design:
    - (b) Sample size:
  - 3.2. At retail level
    - (a) Sampling design:
    - (b) Sample size:
  - 3.3. At border control posts
    - (a) Sampling design:
    - (b) Sample size:
4. Antimicrobial susceptibility testing
  - 4.1. Number of isolates to be tested
  - 4.2. Analytical methods for detection and antimicrobial susceptibility testing
5. Specific monitoring of ESBL- or AmpC- or CP-producing *E. coli*...
  - 5.1. Methods for detection of presumptive ESBL- or AmpC- or CP-producing...
  - 5.2. Quantitative method to assess the proportion of ESBL- or AmpC-producing...
6. Alternative method

7. Quality control, storage of the isolates and confirmatory testing

PART B

Reporting

1. General provisions for reporting of the data
2. Reporting dataset
  - 2.1. Reporting antimicrobial susceptibility testing results
  - 2.2. Reporting WGS testing results

**Changes to legislation:** There are currently no known outstanding effects for the  
Commission Implementing Decision (EU) 2020/1729. (See end of Document for details)

---

- (1) [OJ L 325, 12.12.2003, p. 31.](#)
- (2) Commission Implementing Decision 2013/652/EU of 12 November 2013 on the monitoring and reporting of antimicrobial resistance in zoonotic and commensal bacteria ([OJ L 303, 14.11.2013, p. 26](#)).
- (3) COM/2017/0339 final.
- (4) DG(SANTE) 2019-6789.
- (5) *EFSA Journal* 2019;17(6):5709.

**Changes to legislation:**

There are currently no known outstanding effects for the Commission Implementing Decision (EU) 2020/1729.